Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Core Insights - Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, with a significant emphasis on developing new therapeutics targeting the DDR pathway for cancer treatment [1][3] Company Overview - Aprea's lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor aimed at solid tumor indications [3] - The company has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and is targeting FDA clearance of its IND during Q1 2024 [3] Event Participation - Dr. Oren Gilad, President and CEO of Aprea, will present at the 7th DDR Inhibitors Summit from January 30 to February 1, 2024, in Boston, MA [1] - The presentation titled "Prioritizing Patient Selection for Combination Studies to Optimize Treatments" is scheduled for February 1, 2024, at 9 am ET [2] - Following the presentation, there will be a roundtable panel discussion on defining clinical success for current and next-generation DDR inhibitors [2]